Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

KKR, Stonepeak bid deadline for Assura extended

(Sharecast News) - Assura said on Friday that the deadline by which investment firms KKR and Stonepeak must announce a firm offer for the group has been extended to allow the consortium more time for due diligence. Assura announced on Monday that it was "minded to recommend" an improved, £1.61bn cash takeover proposal from the consortium.

The proposal was improved by 2.9% to 49.4p per share.

Under UK takeover rules, KKR and Stonepeak had until the end of play on Friday to either announce a firm intention to make an offer or walk away. However, this deadline has now been pushed back to 11 April.

Assura said the extension was requested "in order to facilitate ongoing discussions with the consortium and to provide additional time for the consortium to progress its due diligence".

The company also announced on Monday that it had received an indicative, non-binding proposal from Primary Health Properties about a possible all-share combination, which it rejected.

It said the cash offer from KKR was more attractive than the PHP proposal "as it provides shareholders with the opportunity to receive cash consideration at a significantly higher value per share than the proposal from PHP and with materially less risk".

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.